Jun. 5 at 8:34 AM
$ABEO The negatives as I see them following yesterday’s call:
1. Still only 2 active QTC’s with the remainder expecting to come online throughout Q3.
2. Shorts will stay another quarter suppressing the share price.
3. Profitability in June confirmed but framed more as luck due to the way in which the treatments fell, not expecting the same consistent pattern until more QTC’s start treating patients.
Positives:
1. 95% payer coverage, zero push back or denials so far.
2. Zero manufacturing floors.
3. 100 patients identified, 20 moving through the funnel and 2 paid treatments expected for most patients confirming TAM from 750-1,500 US.
4. Even though ramp up is slower by my initial hopes by almost 1.5 quarters I still couldn’t identify a stock I’m as confident in tripling my position of 16k shares at
$4.35 within the next 12 months.
